Gland Pharma reported strong Q1 FY26 results with rising profitability, improved margins, and growth across regulated markets and product launches.

• Revenue rose 7.41% YoY to Rs 1,505.62 crore; EBITDA margin improved to 24% from 19% last year.
• Europe, Canada, and India showed strong revenue growth; the US market declined slightly by 2.42% YoY.
• 12 new molecules launched, 9 ANDAs approved; R&D spend stood at Rs 46 crore, 4.4% of total revenue.